Carlos Bais

7.0k citations

38 papers · 4.1k indexed · 2 hit papers · h-index 20

Co-authors: Enrique A. Mesri J. Silvio Gutkind Napoleone Ferrara Jenny Yao Ethel Cesarman Leandros Arvanitakis Xiumin Wu Omar A. Coso
Topics: Viral-associated cancers and disorders (6 papers)Cancer Genomics and Diagnostics (6 papers)Cancer, Hypoxia, and Metabolism (5 papers)
Cited by: Aging Oncology Cancer Research
Journals: Nature Science Cell
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Carlos Bais

37 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator

1998 677 citations Carlos Bais, Bianca Santomasso et al. Nature profile →
Bv8 regulates myeloid-cell-dependent tumour angiogenesis

2007 522 citations Xiumin Wu, Jenny Yao et al. Nature profile →

Peers

Countries citing papers authored by Carlos Bais

Since Specialization

Citations

This map shows the geographic impact of Carlos Bais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Bais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Bais more than expected).

Fields of papers citing papers by Carlos Bais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Bais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Bais. The network helps show where Carlos Bais may publish in the future.

Co-authorship network of co-authors of Carlos Bais

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Bais. A scholar is included among the top collaborators of Carlos Bais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Bais. Carlos Bais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer 2025 ·Nature Communications ·Xueping Qu,Habib Hamidi,Radia Marie Johnson,Ethan Sokol,(unknown),Cathy Eng,(unknown),Johanna C. Bendell,Smruthy Sivakumar,Bünyamin Kaplan,Felipe de Sousa e Melo,Andrew Mancini,Matthew Wongchenko,Yi Shi,David S. Shames,Yibing Yan,Fortunato Ciardiello,Carlos Bais	3
2	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer 2022 ·Nature Communications ·Radia Marie Johnson,Xueping Qu,(unknown),Ling‐Yuh Huw,Avinashnarayan Venkatanarayan,Ethan Sokol,Fang‐Shu Ou,Nnamdi Ihuegbu,Oliver A. Zill,Omar Kabbarah,Lisa Wang,Richard Bourgon,Felipe de Sousa e Melo,(unknown),Anneleen Daemen,Alan P. Venook,Federico Innocenti,Heinz‐Josef Lenz,Carlos Bais	24
3	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B 2021 ·PLoS ONE ·Anneleen Daemen,(unknown),Thomas Sandmann,Congfen Li,Linda J.W. Bosch,William O’Gorman,Yijin Li,Amelia Au‐Yeung,Chikara Takahashi,Omar Kabbarah,Richard Bourgon,Priti S. Hegde,Carlos Bais,Meghna Das Thakur	4
4	Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma 2020 ·Neuro-Oncology ·Radia Marie Johnson,Heidi Phillips,Carlos Bais,Cameron Brennan,Timothy F. Cloughesy,Anneleen Daemen,Ulrich Herrlinger,Robert B. Jenkins,Albert Lai,Christoph Mancao,Michael Weller,Wolfgang Wick,Richard Bourgon,Josep Garcia	19
5	Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer 2020 ·Nature Communications ·Mélanie Desbois,Akshata R. Udyavar,Lisa Ryner,Cleopatra Kozlowski,Yinghui Guan,Milena Dürrbaum,Shan Lu,Jean‐Philippe Fortin,Hartmut Koeppen,James Ziai,Ching‐Wei Chang,Shilpa Keerthivasan,Marie Plante,Richard Bourgon,Carlos Bais,Priti S. Hegde,Anneleen Daemen,Shannon J. Turley,Yulei Wang	139
6	Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations 2017 ·Pharmaceutical Medicine ·Rajiv Raja,Young S. Lee,Katie Streicher,James R. W. Conway,Song Wu,Sriram Sridhar,(unknown),Hao Liu,Brandon W. Higgs,Philip Z. Brohawn,Carlos Bais,Bahija Jallal,Koustubh Ranade	3
7	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation 2016 ·European Journal of Cancer ·David Miles,David Cameron,Igor Bondarenko,(unknown),Juan Carlos Alcedo,R.I. Lopez,Seock‐Ah Im,Jean‐Luc Canon,Yaroslav Shparyk,Denise A. Yardley,Norikazu Masuda,Jungsil Ro,Neelima Denduluri,Stanislas Hubeaux,Cheng S. Quah,Carlos Bais,Joyce O’Shaughnessy	92
8	Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer 2015 ·Clinical Cancer Research ·Lisa Ryner,Yinghui Guan,Ron Firestein,Yuanyuan Xiao,(unknown),Christina Rabe,Shan Lu,(unknown),Ling‐Yuh Huw,Mark R. Lackner,Ling Fu,Lukas C. Amler,Carlos Bais,Yulei Wang	86
9	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial 2015 ·Journal of Clinical Oncology ·Thomas Sandmann,Richard Bourgon,Josep Garcia,Congfen Li,Timothy F. Cloughesy,Olivier Chinot,Wolfgang Wick,Ryo Nishikawa,Warren Mason,Roger Henriksson,Frank Saran,Albert Lai,N. Moore,Samir Kharbanda,Franklin Peale,Priti S. Hegde,Lauren E. Abrey,Heidi Phillips,Carlos Bais	208
10	Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC). 2015 ·Journal of Clinical Oncology ·Michael J. Birrer,YounJeong Choi,Mark F. Brady,Robert S. Mannel,Robert A. Burger,Wei Wei,Amreen Husain,Carlos Bais,(unknown)	21
11	Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors 2014 ·Cell ·Diego O. Croci,Juan P. Cerliani,Tomás Dalotto‐Moreno,Santiago P. Méndez‐Huergo,Iván Mascanfroni,Sebastián Dergan‐Dylon,Marta A. Toscano,Julio J. Caramelo,Juan J. García‐Vallejo,Jing Ouyang,Enrique A. Mesri,Melissa R. Junttila,Carlos Bais,Margaret A. Shipp,Mariana Salatino,Gabriel A. Rabinovich	414
12	Phosphoproteomic Analysis Implicates the mTORC2-FoxO1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases 2013 ·Science Signaling ·Guanglei Zhuang,Kebing Yu,Zhaoshi Jiang,Alicia S. Chung,Jenny Yao,Connie Ha,Karen Toy,Robert Soriano,Benjamin Haley,Elizabeth Blackwood,Deepak Sampath,Carlos Bais,Jennie R. Lill,Napoleone Ferrara	60
13	Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway 2012 ·The EMBO Journal ·Guanglei Zhuang,Xiumin Wu,Zhaoshi Jiang,Ian Kasman,Jenny Yao,Yinghui Guan,Jason Oeh,Zora Modrušan,Carlos Bais,Deepak Sampath,Napoleone Ferrara	403
14	Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy 2011 ·Proceedings of the National Academy of Sciences ·Jenny Yao,Xiumin Wu,Guanglei Zhuang,Ian Kasman,(unknown),Vernon T. Phan,Masabumi Shibuya,Napoleone Ferrara,Carlos Bais	81
15	Crosstalk Between the EGFR and LIN-12/Notch Pathways in C. elegans Vulval Development 2004 ·Science ·Andrew S. Yoo,Carlos Bais,Iva Greenwald	214
16	Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR 2003 ·Cancer Cell ·Carlos Bais,Albert Van Geelen,Pîlar Eroles,(unknown),Chiara Chiozzini,Sérgio Dias,Roy L. Silverstein,Shahin Rafii,Enrique A. Mesri	194
17	The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. 2000 ·PubMed ·Akrit Sodhi,Silvia Montaner,V. Patel,Muriel Zohar,Carlos Bais,Enrique A. Mesri,J. Silvio Gutkind	373
18	G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator 1998 ·Nature ·Carlos Bais,Bianca Santomasso,Omar A. Coso,Leandros Arvanitakis,(unknown),J. Silvio Gutkind,Adam S. Asch,Ethel Cesarman,Marvin C. Gershengorn,Enrique A. Mesri	27
19	Inhibition of Constitutive Signaling of Kaposi's Sarcoma–associated Herpesvirus G Protein–Coupled Receptor by Protein Kinases in Mammalian Cells in Culture 1998 ·The Journal of Experimental Medicine ·Elizabeth Geras‐Raaka,Leandros Arvanitakis,Carlos Bais,Ethel Cesarman,Enrique A. Mesri,Marvin C. Gershengorn	66
20	G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activatorbreakdown → 1998 ·Nature ·Carlos Bais,Bianca Santomasso,Omar A. Coso,Leandros Arvanitakis,(unknown),J. Silvio Gutkind,Adam S. Asch,Ethel Cesarman,(unknown),Enrique A. Mesri	677

About Carlos Bais

Carlos Bais is a scholar working on Cancer Research, Oncology and Aging, having authored 38 papers that have together received 4.1k indexed citations. Recurring topics across this work include Viral-associated cancers and disorders (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). The work is most often cited by research in Aging (126 citations), Oncology (1.9k citations) and Cancer Research (967 citations). Carlos Bais has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Enrique A. Mesri, J. Silvio Gutkind, Napoleone Ferrara, Jenny Yao, Ethel Cesarman, Leandros Arvanitakis, Xiumin Wu, Omar A. Coso, Iva Greenwald and Adam S. Asch. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact